Department of Urology, University of Montreal Health Center (CHUM), Montreal, Quebec, Canada.
Curr Opin Support Palliat Care. 2012 Sep;6(3):316-21. doi: 10.1097/SPC.0b013e328354a1d8.
The purpose of this article is to review the recent literature concerning obstructive uropathy from advanced cancer. This factor is relevant as it is often a difficult task for physicians to estimate a patient's life expectancy and evaluate the possible benefit of urinary diversion. Recent research has addressed this issue. We now have objective criteria to stratify the possible benefit of urinary diversion in patients with malignant obstructive nephropathy.
When dealing with ureteric obstruction treatment must be individualized and risk stratification is of paramount importance. There is no clear evidence that urinary diversion improves quality of life and treatment decisions must be individualized. The decision to treat obstructive nephropathy in the palliative setting should include the patient, his family and members of the support team.
Ureteric stents and percutaneous nephrostomies are the preferred initial treatment options, although stent infection, encrustation and blockages are common problems. New compression-resistant metallic stents seem promising for patients with a malignant disease who require long-term urinary drainage. When more conservative measures have failed, supra-vesical reconstruction and diversion may be an option.
本文旨在回顾有关晚期癌症引起的梗阻性尿路病的最新文献。这一因素很重要,因为医生通常很难估计患者的预期寿命并评估尿流改道的可能获益。最近的研究已经解决了这个问题。我们现在有客观的标准来对恶性梗阻性肾病患者的尿流改道获益进行分层。
在处理输尿管梗阻时,必须个体化治疗,风险分层至关重要。目前尚无明确证据表明尿流改道能提高生活质量,治疗决策必须个体化。在姑息治疗中决定是否治疗梗阻性肾病时,应包括患者、其家属和支持团队成员。
输尿管支架和经皮肾造瘘术是首选的初始治疗方法,尽管支架感染、结石形成和阻塞是常见问题。对于需要长期尿路引流的恶性疾病患者,新型抗压金属支架似乎很有前途。当更保守的措施失败时,膀胱上重建和分流可能是一种选择。